Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

Summary

To evaluate the safety and tolerability of MSC\_apceth\_101.

Timeline

Start

2013-10

Primary completion

2016-09-07

Completion

2016-09-07

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment terminated after 13 patients (14 planned); further patients did not meet eligibility criteria to receive autologous IMP”

Drugs

Indications